699 related articles for article (PubMed ID: 29515238)
21. Update from the latest WHO classification of MPNs: a user's manual.
Passamonti F; Maffioli M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):534-542. PubMed ID: 27913526
[TBL] [Abstract][Full Text] [Related]
22. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
Eliaçık E; Işık A; Aksu S; Üner A; Büyükaşık Y; Sayınalp N; Göker H; Özcebe OI; Haznedaroğlu İC
Turk J Haematol; 2015 Jun; 32(2):163-7. PubMed ID: 26316485
[TBL] [Abstract][Full Text] [Related]
23. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.
Barosi G; Vannucchi AM; De Stefano V; Pane F; Passamonti F; Rambaldi A; Saglio G; Barbui T; Tura S
Leuk Res; 2014 Feb; 38(2):155-60. PubMed ID: 24378116
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].
Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090
[No Abstract] [Full Text] [Related]
25. From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management.
Pemmaraju N; Moliterno AR
Am Soc Clin Oncol Educ Book; 2015; ():139-45. PubMed ID: 25993152
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
27. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.
Marchetti M; Barosi G; Cervantes F; Birgegård G; Griesshammer M; Harrison C; Hehlmann R; Kiladjian JJ; Kröger N; McMullin MF; Passamonti F; Vannucchi A; Barbui T
Leukemia; 2017 Apr; 31(4):882-888. PubMed ID: 27740634
[TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
29. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
Bjørn ME; Hasselbalch HC
Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
[TBL] [Abstract][Full Text] [Related]
31. [Myeloproliferative neoplasms - Update on diagnosis and treatment].
Meyer SC; Drexler B; Skoda RC
Ther Umsch; 2019; 76(9):487-495. PubMed ID: 32157965
[TBL] [Abstract][Full Text] [Related]
32. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
33. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.
Hoffman R; Prchal JT; Samuelson S; Ciurea SO; Rondelli D
Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):64-72. PubMed ID: 17222772
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Takagi S; Masuoka K; Uchida N; Kurokawa M; Nakamae H; Imada K; Iwato K; Ichinohe T; Atsuta Y; Takami A; Yano S
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2208-2213. PubMed ID: 27667010
[TBL] [Abstract][Full Text] [Related]
36. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
[TBL] [Abstract][Full Text] [Related]
37. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Maffioli M; Mora B; Passamonti F
Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
[TBL] [Abstract][Full Text] [Related]
38. The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.
Slot S; van de Donk NWCJ; Otten RHJ; Boden BJH; Zijlstra J; Raijmakers PGHM; Zweegman S
Cancer Imaging; 2021 Apr; 21(1):36. PubMed ID: 33879266
[TBL] [Abstract][Full Text] [Related]
39. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
40. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]